Skip to main content
. 2021 Sep 8;10:100222. doi: 10.1016/j.lanepe.2021.100222

Table 5.

Impact of adherence to antithrombotic therapy on risk of stroke and bleeding in patients with chronic liver disease (CLD) compared with those without CLD as a reference. Analyses for risk of stroke were performed based on patients stratified according to the time they spent not taking medications. Analyses for risk of bleeding were performed in patients who were adherent. Adjusted hazard ratios (HRs) are reported.

Anticoagulant therapy
HR Lower CI Upper CI P value Outcome
Not taking medication for < 1 week
With CLD 1.435 0.943 2.182 0.092 Stroke
Not taking medication for 1 week to 1 month
With CLD 0.802 0.258 2.498 0.70 Stroke
Not taking medication for 1 month to 3 months
With CLD 1.129 0.281 4.534 0.86 Stroke
Not taking medication for 3 months to 6 months
With CLD 1.097 0.649 1.854 0.73 Stroke
Not taking medication for > 6 months
With CLD 1.143 0.852 1.533 0.37 Stroke
Patients who were adherent (PDC > 80%)
With CLD 1.338 0.959 1.866 0.086 Bleeding

Antiplatelet therapy
HR Lower CI Upper CI P value Outcome

Not taking medication for < 1 week
With CLD 1.454 1.187 1.781 0.00030 Stroke
Not taking medication for 1 week to 1 month
With CLD 1.587 0.954 2.638 0.075 Stroke
Not taking medication for 1 month to 3 months
With CLD 1.058 0.549 2.038 0.87 Stroke
Not taking medication for 3 months to 6 months
With CLD 1.422 1.141 1.772 0.0017 Stroke
Not taking medication for > 6 months
With CLD 1.303 1.116 1.521 0.00082 Stroke
Patients who were adherent (PDC > 80%)
With CLD 2.021 1.729 2.363 < 0.0001 Bleeding